Skip to Content

Twirla Approval Status

  • FDA approved: No
  • Brand name: Twirla
  • Generic name: ethinyl estradiol and levonorgestrel
  • Dosage form: Transdermal System
  • Company: Agile Therapeutics, Inc.
  • Treatment for: Birth Control

Twirla (ethinyl estradiol and levonorgestrel transdermal system) is an investigational low-dose combined hormonal contraceptive.

Development Status and FDA Approval Process for Twirla

DateArticle
Jun 27, 2017Agile Therapeutics Resubmits New Drug Application for its Transdermal Contraceptive Patch, Twirla
May  6, 2017Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla
Oct 26, 2010Agile Therapeutics Announces Study Results Demonstrating Contraceptive Patch AG200-15 Delivers a Low Dose of Estrogen
Dec  9, 2008Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
Sep  3, 2008Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide